Latest Breaking News On - Jonathan zalevsky - Page 5 : comparemela.com

Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

/PRNewswire/ Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for.

San franciscoUnited statesDavid rosenVivian wuJonathan zalevskyMerck kgaExchange commission onSociety for immunotherapy of cancerPfizer incNektar therapeuticsMerck kgaaResearch developmentSenior vice presidentChief researchDevelopment officerInterferon gamma drug candidate

Nektar Therapeutics (NKTR) Presents Preclinical Data for NKTR-288

Nektar Therapeutics (NKTR) Presents Preclinical Data for NKTR-288
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jonathan zalevskyMerck kgaSociety for immunotherapy of cancerMerck kgaaResearch developmentSenior vice presidentChief researchDevelopment officerInterferon gamma drug candidate

Nektar Therapeutics (NKTR) and Collaborators Announces Publication of NKTR-255 Data

Nektar Therapeutics (NKTR) and Collaborators Announces Publication of NKTR-255 Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New south walesStanford universityUnited statesSan franciscoVivian wuJonathan zalevskyFred hutchinson cancer centerAmerican society of hematologyCancer immunotherapy at sydney medical schoolExchange commission onNektar therapeuticsResearch developmentBlood advancesAmerican societyChief researchDevelopment officer

KBC Group NV Has $62,000 Stock Position in Nektar Therapeutics (NASDAQ:NKTR)

KBC Group NV boosted its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR – Get Rating) by 75.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,233 shares of the biopharmaceutical company’s stock after buying an additional 6,979 shares during the period. KBC Group NV’s […]

United statesHowardw robinJonathan zalevskyKbc groupAlaska department of revenueNektar therapeuticsSwiss national bankOregon public employees retirement fundExchange commissionJpmorgan chase coNektar therapeutics company profileWalleye capitalGet ratingPublic employees retirement fundNational bankAlaska department

-$1 00 EPS Expected for Nektar Therapeutics (NASDAQ:NKTR) This Quarter

Analysts expect that Nektar Therapeutics (NASDAQ:NKTR – Get Rating) will post earnings per share of ($1.00) for the current quarter, Zacks reports. Six analysts have provided estimates for Nektar Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.16) and the highest estimate coming in at ($0.67). Nektar Therapeutics posted earnings of ($0.69) per […]

United statesHowardw robinJonathan zalevskySecurities exchange commissionNektar therapeuticsManufacturers life insurance companyZacks investment researchGs investments incJpmorgan chase coCanaccord genuity groupNektar therapeutics company profile get ratingGet ratingNektar therapeuticGenuity groupExchange commissionState retirement system